325 related articles for article (PubMed ID: 34426410)
1. Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.
Anoshchenko O; Storelli F; Unadkat JD
Drug Metab Dispos; 2021 Oct; 49(10):919-928. PubMed ID: 34426410
[TBL] [Abstract][Full Text] [Related]
2. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
3. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
Storelli F; Anoshchenko O; Unadkat JD
Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
[TBL] [Abstract][Full Text] [Related]
4. Successful Prediction of Fetal Exposure to Dual BCRP/P-gp Drug Substrates Using the Efflux Ratio-Relative Expression Factor Approach and PBPK M&S.
Balhara A; Yin M; Unadkat JD
Clin Pharmacol Ther; 2024 May; 115(5):1044-1053. PubMed ID: 38124355
[TBL] [Abstract][Full Text] [Related]
5. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome.
Anoshchenko O; Milad MA; Unadkat JD
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1057-1070. PubMed ID: 34273255
[TBL] [Abstract][Full Text] [Related]
6. Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.
Balhara A; Kumar AR; Unadkat JD
J Clin Pharmacol; 2022 Sep; 62 Suppl 1(Suppl 1):S94-S114. PubMed ID: 36106781
[TBL] [Abstract][Full Text] [Related]
7. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
8. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
Sato S; Matsumiya K; Tohyama K; Kosugi Y
AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
[TBL] [Abstract][Full Text] [Related]
9. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
10. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
Sato S; Tohyama K; Kosugi Y
Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
[TBL] [Abstract][Full Text] [Related]
11. Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics.
Anoshchenko O; Prasad B; Neradugomma NK; Wang J; Mao Q; Unadkat JD
Drug Metab Dispos; 2020 Sep; 48(9):735-741. PubMed ID: 32591415
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.
Zhang Z; Unadkat JD
Drug Metab Dispos; 2017 Aug; 45(8):939-946. PubMed ID: 28049636
[TBL] [Abstract][Full Text] [Related]
14. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
[TBL] [Abstract][Full Text] [Related]
15. Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model.
Kosugi Y; Mizuno K; Santos C; Sato S; Hosea N; Zientek M
AAPS J; 2021 May; 23(4):72. PubMed ID: 34008121
[TBL] [Abstract][Full Text] [Related]
16. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
[TBL] [Abstract][Full Text] [Related]
17. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
18. Maternal and Fetal Exposure to (-)-Δ
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2023 Mar; 51(3):269-275. PubMed ID: 36446608
[TBL] [Abstract][Full Text] [Related]
19. Understanding the Mechanism and Extent of Transplacental Transfer of (-)-∆
Kumar AR; Sheikh ED; Monson JW; Ligon SE; Talley RL; Dornisch EM; Howitz KJ; Damicis JR; Ieronimakis N; Unadkat JD
Clin Pharmacol Ther; 2023 Aug; 114(2):446-458. PubMed ID: 37278090
[TBL] [Abstract][Full Text] [Related]
20. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
